Paige pathology AI products cleared for Europe

By LabPulse.com staff writers

November 13, 2019 -- Paige's Paige Insight artificial intelligence (AI)-native digital pathology slide viewer and Paige Prostate module for prostate cancer detection have both received the CE Mark for primary diagnosis, paving the way for use in Europe.

The company is developing general and organ-specific modules for the viewer that aid in cancer detection and tumor segmentation, among other functions; the prostate is the first focus. The prostate module helps pathologists find cancer more quickly, and it enables real-time quality review of cases, according to the company.

Both products are ready to ship in Europe, Paige said.

Paige Prostate shown on Insight
Pathologists can interact with AI to streamline their workflow, with assistance for detecting prostate cancers. Image courtesy of Paige.
PathAI reports algorithm on par in PD-L1 immunotherapy studies
PathAI reported that its pathology artificial intelligence algorithm performed on par or better than board-certified pathologists in retrospective immunotherapy...
AI wins some -- and loses some -- in test against pathologists
A novel artificial intelligence (AI) algorithm outperformed pathologists in differentiating ductal carcinoma in situ from atypical hyperplasia, a job...
Paige touts paper in Nature Medicine on AI for pathology
Pathology artificial intelligence (AI) software developer Paige is highlighting a paper published July 15 in Nature Medicine that indicates the...
Artificial intelligence takes root in pathology
Artificial intelligence -- the simulation of human intelligence processes by software -- is reaching commercial pathology labs and has begun to significantly...
Smaller labs eye digital pathology options to improve workflow
As workloads increase in laboratory medicine, some pathology labs have considered harnessing new technologies to improve workflow and efficiency. One...

Copyright © 2019 LabPulse.com

Last Updated np 11/13/2019 1:06:25 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email